About
Astellas Pharma Inc. (TSE: 4503) is a Tokyo-based global pharmaceutical company formed in April 2005 through the merger of Yamanouchi and Fujisawa, developing and commercializing therapies in oncology, ophthalmology, urology, immunology and women's health across 70+ countries. Its in-house Human-in-the-Loop discovery platform Mahol-A-Ba combines AI image analysis with automated cell-culture robotics.
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Astellas Pharma
Astellas Pharma Inc. (TSE: 4503) is a Tokyo-based global pharmaceutical company formed in April 2005 through the merger of Yamanouchi and Fujisawa, developing and commercializing therapies in oncology, ophthalmology, urology, immunology and women's health across 70+ countries. Its in-house Human-in-the-Loop discovery platform Mahol-A-Ba combines AI image analysis with automated cell-culture robotics.
—
United States
BusinessLatest roundTotal raisedDate- Pathos AI
Uses artificial intelligence and robotic automation to accelerate the development of targeted therapies for solid tumors
Series D+ · $602M · 2026-10 · Valuation $3.0B
$602MValuation $3.0B - Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M - LifeMine Therapeutics
A clinical-stage precision drug discovery company based on fungal genome mining, developing novel therapies in transplantation and immunology.
Series D+ · $558M · 2026-08
$558M
China
BusinessLatest roundTotal raisedDate- ATLATL Innovation Center
R&D infrastructure and incubation for early-stage biopharma: shared labs, resident scientists and project management, GMP process optimization, preclinical pharmacology and toxicology, plus an AI drug screening module, for biopharma startups, university and institute spinout teams and multinational pharma
— - Phil Rivers Technology
Computational medicine and life world models using AI and high-performance computing to simulate disease mechanisms and drug efficacy, systematically discover new oncology targets, assess indications and predict responding patients for novel drug R&D
Series A2 · 2026-08
— - Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M - Cyclana Bio
Tissue-level drug discovery model for treating endometriosis
Pre-Seed · $7M · 2025-10
$7M
Other / unspecified
BusinessLatest roundTotal raisedDateConfirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.